Floatz logo

Encequidar

Metastatic Breast Cancer

Health Hope PharmaSmall moleculePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
73/ 100

Competitive context

890 Active assets in the Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Encequidar is also rated in:

angiosarcomaDormant
CCC
Indicative ·
53 / 100
View asset →
Hormone Receptor Positive TumorDormant
CCC
Indicative ·
53 / 100
View asset →
Hormone Receptor Negative TumorDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →